EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| ChEBI ID | CHEBI:749553 |
| ChEBI Name | daclizumab |
| Stars | |
| Last Modified | 29 June 2026 |
| Submitter | ChEMBL |
| Roles Classification |
|---|
| Biological Roles: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. anti-HIV agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. |
| Applications: | anti-asthmatic agent Any compound that has anti-asthmatic effects. ophthalmology drug Any compound used for the treatment of eye conditions or eye diseases. renoprotective agent Any compound that is able to prevent damage to the kidneys. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. anti-inflammatory agent Any compound that has anti-inflammatory effects. hypoglycemic agent A drug which lowers the blood glucose level. antipsoriatic A drug used to treat psoriasis. anti-anaemic agent A compound which increases either the number of red cells or the amount of haemoglobin in the blood. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| daclizumab (CHEBI:749553) has role anti-anaemic agent (CHEBI:75835) |
| daclizumab (CHEBI:749553) has role anti-asthmatic agent (CHEBI:65023) |
| daclizumab (CHEBI:749553) has role anti-HIV agent (CHEBI:64946) |
| daclizumab (CHEBI:749553) has role anti-inflammatory agent (CHEBI:67079) |
| daclizumab (CHEBI:749553) has role antineoplastic agent (CHEBI:35610) |
| daclizumab (CHEBI:749553) has role antipsoriatic (CHEBI:50748) |
| daclizumab (CHEBI:749553) has role hypoglycemic agent (CHEBI:35526) |
| daclizumab (CHEBI:749553) has role immunosuppressive agent (CHEBI:35705) |
| daclizumab (CHEBI:749553) has role ophthalmology drug (CHEBI:66981) |
| daclizumab (CHEBI:749553) has role renoprotective agent (CHEBI:231911) |
| daclizumab (CHEBI:749553) is a organic molecular entity (CHEBI:50860) |
| Synonyms | Source |
|---|---|
| Daclizumab | ChEMBL |
| Daclizumab beta | ChEMBL |
| RO 24-7375 | ChEMBL |
| RO-24-7375 | ChEMBL |
| Brand Names | Source |
|---|---|
| Zenapax | ChEMBL |
| Zinbryta | ChEMBL |